The Challenges of Developing a Therapy for Pregnant Women with A Rare Condition

Katie Abouzahr, vice president of the autoantibody portfolio and maternal fetal disease area leader for Johnson and Johnson, discusses hemolytic disease of the fetus and newborn, the challenges of developing a therapy for a rare condition in pregnant women, and why its experimental therapy nipocalimab has the potential to be a pipeline in a product. https://globalgenes.org/raredaily/the-challenges-of-developing-a-therapy-for-pregnant-women-with-a-rare-condition/